Research and Development

Shire has withdrawn the European marketing application for its Attention Deficit Hyperactivity Disorder (ADHD) patch product Daytrana. The product's active …

An FDA committee has recommended Sanofi-Aventis' new atrial fibrillation treatment Multaq, the company's most important late-stage drug. The FDA cardiovascular …

Anti-blood clotting drug Xarelto could fail to win approval in the US due to safety concerns. The FDA has convened …

The US moved one step closer to creating a market for biosimilars – substitutable versions of branded biologic drugs – …

A leading public health expert has been appointed as the new head of the FDA. President Obama has selected Dr …

The rate of patent applications refused in Europe has risen to an all time high, as authorities target "evergreening" of …

Portfolio planning should be a practical process that delivers a programme of work to take you to sunnier shores. All …

Around one in five European biotech companies could go bust by the end of 2009 if new funding doesn't emerge …

The chances of approval for Genzyme's new Pompe disease drug Lumizyme have diminished dramatically after the US Food and Drug …

How did you find your way into your current role? On return from a working holiday to New Zealand I …

Five establishments have been named by the government as Academic Health Science Centres (AHSCs). The centres – UCL Partners, Cambridge …

President Obama has lifted the US ban on federal funding for new stem cell research, signalling another marked departure in …

In January, leading pharmaceutical experts attended the 2009 Forum Institute seminar on biosimilars, and the challenges involved in their successful …

US company StemCells Inc is to expand its capabilities in the field with the purchase of UK based Stem Cell …